STOCK TITAN

10X Genomics, Inc. - TXG STOCK NEWS

Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.

Overview

10X Genomics, Inc. is a pioneering life science technology company that builds integrated systems to enable high-resolution analysis of biological systems. The company's suite of instruments, consumables, and software platforms are designed to empower researchers by unlocking the complex details of single cell biology and spatial transcriptomics. Through its advanced solutions, 10X Genomics facilitates breakthroughs in oncology, immunology, neuroscience, and other fields by allowing scientists to conduct experiments that dissect biological intricacies at an unprecedented scale and accuracy.

Integrated Solutions for Advanced Research

At the core of 10X Genomics’ approach is a commitment to providing comprehensive, integrated solutions. Their platforms merge state-of-the-art hardware with innovative software that enables both single cell analysis and spatial profiling of tissues. This combination of high-performance instrumentation with intuitive analytical tools equips researchers to unravel cellular heterogeneity and examine spatial relationships within tissues. These capabilities are essential for understanding disease mechanisms, drug responses, and the multifaceted nature of biological processes.

Core Technologies and Innovation

10X Genomics has established a strong reputation for its ability to translate complex biological queries into actionable information. Its technologies are built around a modular design that includes microfluidic systems, robust reagents, and dedicated software ecosystems. The company emphasizes the importance of achieving resolution and scale in biological analysis, ensuring that each cell, and even its spatial context, is captured in detail. Through continual innovation, the company has transformed conventional research approaches and provided researchers with tools to perform high-throughput experiments on a scale that was once considered unattainable.

Market Position and Research Impact

Positioned within the competitive landscape of life science technology, 10X Genomics stands out due to its focus on both single cell and spatial methodologies. Academic institutions, translational researchers, and biopharmaceutical companies rely on its accurate and high-resolution data to fuel discoveries that redefine our understanding of biology. The company’s products are integral to research initiatives that explore the underlying biology of diseases, aiding in the identification of novel biomarkers and therapeutic targets. Through its collaborative efforts with leading research institutions, the company continues to contribute to a growing body of scientific literature, thereby reinforcing its role as a key enabler of modern biological research.

Product Platforms and Applications

The multifaceted product portfolio of 10X Genomics is designed to meet the evolving needs of the life sciences community. The company’s instruments and consumables are optimized for experiments that require detailed analysis of RNA expression, genomic variation, and tissue architecture. These capabilities are not only instrumental in basic research settings but also in translational studies where precision and reproducibility are paramount. Researchers benefit from an ecosystem where each component—from reagent formulation to data analysis—is engineered to offer a seamless workflow, thereby accelerating the pace of scientific discovery.

Scientific Rigor and Data Quality

The technologies developed by 10X Genomics are backed by extensive validation and have been cited in a significant number of scientific publications. The company’s commitment to quality and precision is reflected in its ongoing efforts to refine instruments and protocols to capture the experimental complexity inherent in biological research. By maintaining high standards of reproducibility and data integrity, 10X Genomics not only supports reliable research outcomes but also fosters trust within the academic and commercial research communities.

Commitment to Democratizing Access

In addition to technical excellence, 10X Genomics is committed to democratizing access to cutting-edge research tools. By continuously driving down the cost per analysis and simplifying experimental workflows, the company is making sophisticated single cell and spatial analyses accessible across various scales—from pioneering labs in academic institutions to large biopharmaceutical operations. This focus on accessibility ensures that researchers at all stages can capitalize on high-resolution biological insights without compromising on quality or throughput.

Competitive Differentiators

What differentiates 10X Genomics from its peers is a combination of technological innovation, integrated system design, and a deep understanding of biological complexity. The company’s products are engineered with a dual emphasis on performance and ease-of-use, ensuring that researchers can operate at the forefront of technology without extensive technical hurdles. Furthermore, the capacity to perform experiments that capture both cellular individuality and spatial context provides a holistic view of biological systems that is unique in the market.

Experience and Expertise

With a strong scientific team and a rich history of technological milestones, 10X Genomics has positioned itself as an authority in the field of single cell and spatial biology. The company leverages its deep scientific expertise to continually push the boundaries of what is possible, empowering researchers to generate high-quality data and drive powerful discoveries. An extensive network of research collaborations and a history of impactful publications further solidify its reputation as a trusted partner in the journey to unlock the complexities of life.

Conclusion

In summary, 10X Genomics, Inc. offers a robust suite of tools that redefine the landscape of biological research. Its commitment to integrated, high-resolution analysis has transformed the way researchers interrogate biological systems, ultimately advancing our understanding of health and disease. With a clear focus on performance, innovation, and accessibility, the company is well-positioned to remain a cornerstone in the scientific community, delivering reliable solutions that meet the intricate demands of modern research.

Rhea-AI Summary

10x Genomics (Nasdaq: TXG) has announced the acquisition of Tetramer Shop and unveiled new products at its Xperience 2021 event. This marks the fifth acquisition for the firm, aimed at bolstering its immunology efforts. The newly introduced products focus on single-cell analysis, with significant capabilities like the Low Throughput Single Cell Gene Expression solution, expected to lower startup costs by up to 60%. Other upcoming innovations include Chromium X, Visium advancements, and a new cloud platform for data analysis, enhancing accessibility for researchers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
none
-
Rhea-AI Summary

10x Genomics reported Q4 2020 revenue of $112.2 million, a 49% increase from the previous year, and a full-year revenue of $298.8 million, up 22% year-over-year. The company had a gross margin of 83% in Q4, up from 78% in Q4 2019, driven by a shift in product sales. However, operating expenses surged to $502.9 million, resulting in an operating loss of $409.6 million. For 2021, 10x Genomics projects revenue between $480 million and $500 million, reflecting a growth outlook of 61% to 67%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
-
Rhea-AI Summary

10x Genomics (TXG) has announced that it will release its financial results for Q4 and full year ended December 31, 2020, after the market close on February 17, 2021. A conference call to discuss the results and company outlook will begin at 1:30 PM PT. The event will be accessible via webcast on the company's website and archived for replay for 45 days. 10x Genomics focuses on life science technology, providing solutions that enhance biological understanding, serving major global research institutions and pharmaceutical companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
conferences earnings
Rhea-AI Summary

10x Genomics (Nasdaq: TXG) will participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference, scheduled for January 11, 2021, at 7:00 a.m. PT / 10:00 a.m. ET. The company's management will present key information, and interested parties can access a live and archived webcast on their Investors page.

10x Genomics develops integrated solutions for biological research, with products widely adopted by leading research institutions and pharmaceutical companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
conferences
-
Rhea-AI Summary

10x Genomics, Inc. (TXG) reported Q3 2020 revenue of $71.8 million, a 17% increase year-over-year and a 67% increase from Q2 2020. The company made significant acquisitions of ReadCoor and CartaNA, enhancing its capabilities in In Situ analysis. Despite revenue growth, operating expenses surged 124% to $122.7 million, leading to an operating loss of $65.3 million and a net loss of $65.8 million. The company has withdrawn its full-year revenue guidance due to ongoing COVID-19 uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
-
Rhea-AI Summary

10x Genomics (Nasdaq: TXG) will participate in the Stifel Virtual Healthcare Conference on November 16 at 11:40 a.m. PT. The presentation will be accessible via a live and archived webcast on the company’s investors page.

10x Genomics offers advanced products for biological analysis, utilized by 97 of the top 100 research institutions and 19 of the top 20 pharmaceutical companies. With over 1,750 citations in research, the company holds a patent portfolio of more than 825 patents and applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
conferences
Rhea-AI Summary

10x Genomics (TXG) will report its third-quarter financial results on November 10, 2020, post-market. A conference call will follow at 2:00 PM PT to discuss outcomes, business developments, and future outlook.

The event will be available for live audio streaming on the company’s website, with a recording accessible for 45 days thereafter. 10x Genomics specializes in life science technologies, offering comprehensive solutions for biological analysis, widely adopted by leading research institutions and pharmaceutical companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences earnings
-
Rhea-AI Summary

10x Genomics (Nasdaq: TXG) announced a definitive agreement to acquire ReadCoor, a developer of In Situ technologies, for $350 million in cash and stock. This follows the acquisition of CartaNA AB, enhancing 10x's capabilities in In Situ RNA analysis. Together, these acquisitions are expected to develop comprehensive intellectual property and technology in the emerging In Situ field, potentially establishing a new technology platform and broadening customer applications. The ReadCoor acquisition is anticipated to complete later this month, subject to shareholder approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
-
Rhea-AI Summary

10x Genomics, Inc. (NASDAQ: TXG) announced the successful closing of a public offering for 4,600,000 shares of its Class A common stock, including the full exercise of an underwriters’ option for an additional 600,000 shares. Priced at $110.00 per share, the total gross proceeds amounted to $506 million prior to underwriting discounts and expenses. J.P. Morgan Securities LLC, BofA Securities, and Cowen and Company acted as lead managers. Registration statements for this offering were effective as of September 10, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
Rhea-AI Summary

10x Genomics (Nasdaq: TXG) has announced the commercial shipping of its Chromium Single Cell Multiome ATAC + Gene Expression solution, the first product to simultaneously profile a cell's epigenome and transcriptome. This innovative approach enhances research capabilities by directly linking epigenetic programs to gene expression, improving understanding of cell functionality and disease mechanisms. Early adopters include Stanford and Mt. Sinai, emphasizing its potential in studying immune response to cancer and neuropsychiatric diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none

FAQ

What is the current stock price of 10X Genomics (TXG)?

The current stock price of 10X Genomics (TXG) is $8.67 as of April 1, 2025.

What is the market cap of 10X Genomics (TXG)?

The market cap of 10X Genomics (TXG) is approximately 1.1B.

What is the primary focus of 10X Genomics, Inc.?

10X Genomics, Inc. focuses on advancing biological research by providing integrated instruments, consumables, and software for single cell and spatial biology analysis.

How do 10X Genomics' solutions benefit researchers?

Their systems enable researchers to capture high-resolution data on individual cells and spatial context, which is essential for understanding complex biological systems, disease mechanisms, and therapeutic responses.

What makes 10X Genomics' technology stand out in the market?

The company’s emphasis on integrated solutions, which combine high-performance hardware with dedicated software, allows for precise and scalable analysis, differentiating them from competitors in the life sciences sector.

Who are the typical customers of 10X Genomics?

Their typical customers include academic research institutions, translational research labs, and biopharmaceutical companies that require highly detailed cellular and spatial analysis for their studies.

In which research areas are 10X Genomics' products widely used?

Their products are widely used in oncology, immunology, neuroscience, and other fields where understanding cellular complexity and spatial data is crucial to advancing research.

How does 10X Genomics ensure data quality and reproducibility?

The company maintains rigorous quality control through extensive validation of its technologies, ensuring that its instruments and protocols generate high-quality, reproducible data that meet evolving research standards.

What role does innovation play in the company’s strategy?

Innovation is central to 10X Genomics' strategy, as they continuously improve their platforms to reduce costs, enhance performance, and make advanced biological analysis more accessible to a broad range of researchers.

How does 10X Genomics support democratization of advanced research tools?

By lowering the operational costs and streamlining experimental workflows, 10X Genomics makes cutting-edge single cell and spatial biology technologies accessible to both leading research institutions and smaller laboratories.
10X Genomics, Inc.

Nasdaq:TXG

TXG Rankings

TXG Stock Data

1.07B
104.51M
2.14%
96.93%
11.26%
Health Information Services
Laboratory Analytical Instruments
Link
United States
PLEASANTON